- Home
- TSHA vs ICG Comparison
TSHA vs ICG Comparison
Compare TSHA & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ICG
- Stock Information
- Founded
- TSHA 2019
- ICG 2017
- Country
- TSHA United States
- ICG China
- Employees
- TSHA N/A
- ICG N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ICG Semiconductors
- Sector
- TSHA Health Care
- ICG Technology
- Exchange
- TSHA Nasdaq
- ICG Nasdaq
- Market Cap
- TSHA 262.4M
- ICG 230.3M
- IPO Year
- TSHA 2020
- ICG 2023
- Fundamental
- Price
- TSHA $1.24
- ICG $1.67
- Analyst Decision
- TSHA Strong Buy
- ICG Strong Buy
- Analyst Count
- TSHA 8
- ICG 2
- Target Price
- TSHA $6.63
- ICG $9.50
- AVG Volume (30 Days)
- TSHA 2.4M
- ICG 32.4K
- Earning Date
- TSHA 05-13-2025
- ICG 05-15-2025
- Dividend Yield
- TSHA N/A
- ICG N/A
- EPS Growth
- TSHA N/A
- ICG N/A
- EPS
- TSHA N/A
- ICG 0.12
- Revenue
- TSHA $8,333,000.00
- ICG $38,602,978.00
- Revenue This Year
- TSHA N/A
- ICG N/A
- Revenue Next Year
- TSHA N/A
- ICG $603.22
- P/E Ratio
- TSHA N/A
- ICG $14.19
- Revenue Growth
- TSHA N/A
- ICG 242.68
- 52 Week Low
- TSHA $1.05
- ICG $1.60
- 52 Week High
- TSHA $4.32
- ICG $12.04
- Technical
- Relative Strength Index (RSI)
- TSHA 40.35
- ICG 26.92
- Support Level
- TSHA $1.05
- ICG $1.60
- Resistance Level
- TSHA $1.36
- ICG $1.99
- Average True Range (ATR)
- TSHA 0.17
- ICG 0.28
- MACD
- TSHA -0.01
- ICG -0.02
- Stochastic Oscillator
- TSHA 25.68
- ICG 5.43
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.